OA12494A - Inhibitor of monoamine uptake. - Google Patents
Inhibitor of monoamine uptake. Download PDFInfo
- Publication number
- OA12494A OA12494A OA1200300215A OA1200300215A OA12494A OA 12494 A OA12494 A OA 12494A OA 1200300215 A OA1200300215 A OA 1200300215A OA 1200300215 A OA1200300215 A OA 1200300215A OA 12494 A OA12494 A OA 12494A
- Authority
- OA
- OAPI
- Prior art keywords
- methyl
- phenyl
- oxy
- compound
- aminopropane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27373001P | 2001-03-06 | 2001-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA12494A true OA12494A (en) | 2006-05-24 |
Family
ID=23045157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200300215A OA12494A (en) | 2001-03-06 | 2002-02-20 | Inhibitor of monoamine uptake. |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US20040082666A1 (hr) |
| EP (1) | EP1379492B1 (hr) |
| JP (1) | JP2004525912A (hr) |
| KR (1) | KR20030092012A (hr) |
| CN (1) | CN1229331C (hr) |
| AP (1) | AP2003002855A0 (hr) |
| AT (2) | AT414238B (hr) |
| AU (1) | AU2002245385B2 (hr) |
| BR (1) | BR0207716A (hr) |
| CA (1) | CA2440161A1 (hr) |
| CH (1) | CH695982A5 (hr) |
| CZ (1) | CZ20032380A3 (hr) |
| DE (1) | DE60226715D1 (hr) |
| DK (1) | DK200301267A (hr) |
| EA (1) | EA005768B1 (hr) |
| EC (1) | ECSP034760A (hr) |
| EE (1) | EE200300419A (hr) |
| ES (2) | ES2201942B2 (hr) |
| FI (1) | FI20031191A (hr) |
| GB (1) | GB2389851B (hr) |
| HR (1) | HRP20030710A2 (hr) |
| HU (1) | HUP0303341A3 (hr) |
| IL (1) | IL157779A0 (hr) |
| LT (1) | LT5143B (hr) |
| LU (1) | LU91038B1 (hr) |
| LV (1) | LV13119B (hr) |
| NO (1) | NO20033921L (hr) |
| NZ (1) | NZ527431A (hr) |
| OA (1) | OA12494A (hr) |
| PL (1) | PL363840A1 (hr) |
| SE (1) | SE526598C2 (hr) |
| SK (1) | SK10632003A3 (hr) |
| TR (1) | TR200705146T1 (hr) |
| WO (1) | WO2002070457A1 (hr) |
| ZA (1) | ZA200306882B (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0303341A3 (en) * | 2001-03-06 | 2007-03-28 | Lilly Co Eli | Inhibitor of monoamine uptake and pharmaceutical compositions containing it |
| WO2005020976A2 (en) * | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
| CA2548304A1 (en) * | 2003-12-12 | 2005-07-07 | Eli Lilly And Company | Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition |
| WO2011027359A2 (en) * | 2009-07-30 | 2011-03-10 | Matrix Laboratories Ltd | Novel process for the preparation of 4-hydroxy atomoxetine |
| WO2012020418A1 (en) | 2010-08-12 | 2012-02-16 | Matrix Laboratories Ltd | Novel polymorphs of 4-hydroxy atomoxetine hydrochloride |
| DE102013022397A1 (de) | 2013-12-19 | 2016-07-07 | Metrax Gmbh | Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage |
| GR1008819B (el) | 2015-05-22 | 2016-08-01 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου |
| CN107935848B (zh) * | 2017-11-21 | 2020-12-22 | 中国农业科学院兰州畜牧与兽药研究所 | 一种六茜素衍生物及其制备方法和应用 |
| MX2021004883A (es) * | 2018-10-31 | 2021-08-05 | Apnimed Inc Delaware | Metodos y composiciones para tratar apnea del sue?o. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018895A (en) | 1974-01-10 | 1977-04-19 | Eli Lilly And Company | Aryloxyphenylpropylamines in treating depression |
| US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| US4194009A (en) | 1974-01-10 | 1980-03-18 | Eli Lilly And Company | Aryloxyphenylpropylamines for obtaining a psychotropic effect |
| FR2432500A1 (fr) * | 1978-02-24 | 1980-02-29 | Roussel Uclaf | Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments |
| US5112619A (en) * | 1985-11-12 | 1992-05-12 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulation |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| ZA885824B (en) * | 1987-08-14 | 1989-04-26 | Merrell Dow Pharma | Novel antidepressants |
| PH30083A (en) * | 1991-02-25 | 1996-12-27 | Lilly Co Eli | Treatment of lower urinary tract disorders |
| TW514634B (en) | 1997-10-14 | 2002-12-21 | Lilly Co Eli | Process to make chiral compounds |
| WO2000058262A1 (en) | 1999-03-29 | 2000-10-05 | Eli Lilly And Company | Stereospecific method for preparing tomoxetine and intermediates thereof |
| DK1171417T3 (da) | 1999-04-09 | 2006-02-20 | Lilly Co Eli | Fremgangsmåde til fremstilling af 3-aryloxy-3-arylpropylaminer og mellemprodukter deraf |
| EA200300567A1 (ru) * | 2000-11-15 | 2004-10-28 | Эли Лилли Энд Компани | Лечение состояний тревоги |
| HUP0303341A3 (en) * | 2001-03-06 | 2007-03-28 | Lilly Co Eli | Inhibitor of monoamine uptake and pharmaceutical compositions containing it |
-
2002
- 2002-02-20 HU HU0303341A patent/HUP0303341A3/hu unknown
- 2002-02-20 EP EP02713538A patent/EP1379492B1/en not_active Revoked
- 2002-02-20 BR BR0207716-7A patent/BR0207716A/pt not_active IP Right Cessation
- 2002-02-20 WO PCT/US2002/003385 patent/WO2002070457A1/en not_active IP Right Cessation
- 2002-02-20 AT AT0904202A patent/AT414238B/de not_active IP Right Cessation
- 2002-02-20 ES ES200350052A patent/ES2201942B2/es not_active Expired - Fee Related
- 2002-02-20 KR KR10-2003-7011635A patent/KR20030092012A/ko not_active Application Discontinuation
- 2002-02-20 EA EA200300978A patent/EA005768B1/ru not_active IP Right Cessation
- 2002-02-20 CH CH01522/03A patent/CH695982A5/de not_active IP Right Cessation
- 2002-02-20 DE DE60226715T patent/DE60226715D1/de not_active Revoked
- 2002-02-20 CZ CZ20032380A patent/CZ20032380A3/cs unknown
- 2002-02-20 NZ NZ527431A patent/NZ527431A/en unknown
- 2002-02-20 PL PL02363840A patent/PL363840A1/xx not_active Application Discontinuation
- 2002-02-20 OA OA1200300215A patent/OA12494A/en unknown
- 2002-02-20 AT AT02713538T patent/ATE396170T1/de not_active IP Right Cessation
- 2002-02-20 LU LU91038A patent/LU91038B1/fr active
- 2002-02-20 EE EEP200300419A patent/EE200300419A/xx unknown
- 2002-02-20 AP APAP/P/2003/002855A patent/AP2003002855A0/en unknown
- 2002-02-20 GB GB0323169A patent/GB2389851B/en not_active Expired - Fee Related
- 2002-02-20 ES ES02713538T patent/ES2305221T3/es not_active Expired - Lifetime
- 2002-02-20 TR TR2007/05146T patent/TR200705146T1/xx unknown
- 2002-02-20 JP JP2002569778A patent/JP2004525912A/ja not_active Ceased
- 2002-02-20 AU AU2002245385A patent/AU2002245385B2/en not_active Ceased
- 2002-02-20 IL IL15777902A patent/IL157779A0/xx unknown
- 2002-02-20 US US10/468,553 patent/US20040082666A1/en not_active Abandoned
- 2002-02-20 CA CA002440161A patent/CA2440161A1/en not_active Abandoned
- 2002-02-20 SK SK1063-2003A patent/SK10632003A3/sk unknown
- 2002-02-20 CN CNB028060253A patent/CN1229331C/zh not_active Ceased
-
2003
- 2003-08-11 LT LT2003075A patent/LT5143B/lt unknown
- 2003-08-25 FI FI20031191A patent/FI20031191A/fi not_active IP Right Cessation
- 2003-09-02 EC EC2003004760A patent/ECSP034760A/es unknown
- 2003-09-03 SE SE0302361A patent/SE526598C2/sv not_active IP Right Cessation
- 2003-09-03 ZA ZA200306882A patent/ZA200306882B/en unknown
- 2003-09-04 NO NO20033921A patent/NO20033921L/no not_active Application Discontinuation
- 2003-09-04 DK DK200301267A patent/DK200301267A/da not_active Application Discontinuation
- 2003-09-05 HR HR20030710A patent/HRP20030710A2/hr not_active Application Discontinuation
- 2003-09-10 LV LVP-03-100A patent/LV13119B/en unknown
-
2005
- 2005-05-09 US US11/125,348 patent/US7384983B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7384983B2 (en) | Inhibitor of monoamine uptake | |
| US20070032555A1 (en) | Novel aryloxyphenyl-propanamines | |
| US20110288179A1 (en) | Bimatoprost crystalline form i | |
| US9108902B2 (en) | Deuterated 2-amino-3-hydroxypropanoic acid derivatives | |
| JP3708957B2 (ja) | （−）−エゼロリン、（−）−ｎ１−ノルエゼロリンおよび（−）−ｎ１−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩：特異的アセチルコリンエステラーゼ阻害薬としての使用 | |
| US11905276B2 (en) | Bicyclic compound that acts as CRBN protein regulator | |
| CA3160899C (en) | Spiro compound serving as erk inhibitor, and application thereof | |
| ES2893749T3 (es) | Derivados de fumagilol y polimorfos de los mismos | |
| AU2002245385A1 (en) | Inhibitor of monoamine uptake | |
| US20090149544A1 (en) | Alpha-aminoamide derivatives | |
| CN115894456A (zh) | 一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途 | |
| US20110152227A1 (en) | Deuterium labelled derivatives of 3-(2-hydroxy-5-methyphenyl)-n,n-diisopropyl-3-phenylpropylamine and methods of use thereof | |
| AU2007201684A1 (en) | Inhibitor of monoamine uptake | |
| US7183319B2 (en) | Phenylethylamine derivatives and their use in the treatment of melanoma | |
| CN102701992A (zh) | 一种抗肿瘤化合物及其药学上可接受的盐、及制备方法和应用 | |
| US20220033376A1 (en) | Estrogen receptor antagonist | |
| US20080312318A1 (en) | Deuterium-enriched escitalopram | |
| CN115572294B (zh) | 一种氘代氮杂吲哚联吡唑类化合物、药物组合物和用途 | |
| US20240122876A1 (en) | Compositions and methods for the treatment of ocular disorders | |
| JPH0772168B2 (ja) | グアニジノ安息香酸エステル誘導体 |